BRIGHT-4: Is Bivalirudin Poised for a Comeback in STEMI PCI? BRIGHT-4: Is Bivalirudin Poised for a Comeback in STEMI PCI?
Results of the massive Chinese trial strongly favor bivalirudin over heparin but years of practice and cost concerns may be too much to overcome, observers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Bivalirudin Crowned as Better Anticoagulant for Primary PCI in STEMI
(MedPage Today) -- CHICAGO -- Periprocedural anticoagulation with bivalirudin (Angiomax) for a radial-first approach to primary percutaneous coronary intervention (PCI) improved mortality and bleeding risk compared with heparin in the BRIGHT... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 7, 2022 Category: Cardiology Source Type: news
Use of bivalirudin for anticoagulation in interventional cardiovascular procedures
(Cardiovascular Innovations and Applications) In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: 10.15212/CVIA.2017.0045 Zhen Ge, Jaya Chandrasekhar and Roxana Mehran from the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, N.Y., USA consider the use of bivalirudin for anticoagulation in interventional cardiovascular procedures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2018 Category: International Medicine & Public Health Source Type: news
Nod for Aurobindo Pharma to make, market Bivalirudin injection
Citing market reports, the release said the estimated market size of the Bivalirudin injection was USD 101 million for the year ending May 2018. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 30, 2018 Category: Pharmaceuticals Source Type: news
ESC: Unexpected Results with Direct Thrombin Inhibitor in PCI (CME/CE)
(MedPage Today) -- Bivalirudin doesn ' t reduce bleeding in registry-based VALIDATE-SWEDEHEART (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 27, 2017 Category: Cardiology Source Type: news
No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news
BRAVO 3: Still No Place for Bivalirudin in TAVR
(MedPage Today) -- No major interactions with Afib status or valve type in trials (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 14, 2017 Category: Cardiology Source Type: news
BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ BRAVO 3 TAVR and AF: Stroke Risk, Discharge Meds Differ
In the BRAVO-3 trial of patients who had transfemoral TAVR with procedural bivalirudin or heparin, patients with new-onset AF had a much greater stroke risk; there was also an"incredible" variation in discharge meds.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
Analysis looks at role type of valve plays in patient outcomes post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Impact of valve design and bivalirudin vs. unfractionated heparin for anticoagulation in transcatheter aortic valve replacement: Results from the BRAVO-3 trial' were presented today as a late-breaking clinical trial at the Society for CardiovascularAngiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2017 Category: International Medicine & Public Health Source Type: news
Analysis shows increased risk of early stroke with new-onset atrial fibrillation post-TAVR
(Society for Cardiovascular Angiography and Interventions) Results from 'Effect of bivalirudin versus unfractionated heparin in patients with baseline or new-onset atrial fibrillation in transcatheter aortic valve replacement: From the BRAVO-3 randomized trial' were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions in New Orleans. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 11, 2017 Category: International Medicine & Public Health Source Type: news
Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk Bivalirudin in Briefer PCI May Boost Stent Thrombosis Risk
Shorter percutaneous coronary intervention (PCI) procedures are associated with an increased risk of acute stent thrombosis (AST) in patients treated with bivalirudin, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2017 Category: Consumer Health News Tags: Emergency Medicine News Source Type: news
Bivalirudin Ill-Suited for Speedy Stenting?
(MedPage Today) -- More stent thrombosis seen with fast-acting drug in brief procedures (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 2, 2017 Category: Cardiology Source Type: news
Bivalirudin (Angiomax) (Bivalirudin Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 23, 2017 Category: Drugs & Pharmacology Source Type: news
Bivalirudin (Angiomax) (Bivalirudin Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 23, 2017 Category: Drugs & Pharmacology Source Type: news
Intracoronary Bivalirudin in STEMI Patients Treated With PCI Intracoronary Bivalirudin in STEMI Patients Treated With PCI
This report describes a novel off-label protocol for bivalirudin administration in patients with STEMI undergoing PCI. What advantages does it offer over the standard intravenous route?American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 3, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
